Compared side by side
Thymosin Alpha-1 vs thymalin: how they differ
The short answer
The names are alike and both work on the immune system, but they are different substances: thymosin alpha-1 is a single naturally occurring thymic peptide, sold as the prescription drug thymalfasin, and thymalin is a peptide extract of calf thymus from Russia’s bioregulator program. Thymosin alpha-1 is a prescription drug in about 35 countries, mainly for hepatitis B, though not in the US; thymalin has no FDA-approved product, and its human studies, almost all by its developers, are not described as randomized. Thymosin alpha-1 is taken twice a week, and thymalin daily in short courses of commonly 5–10 days.
Side by side
| Compared | Thymosin Alpha-1 | Thymalin |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Tα1, Thymalfasin, Zadaxin | Timalin, Thymaline, Thymus peptide complex |
| What it is | A naturally occurring thymic peptide that fine-tunes the immune system: it helps T-cells mature and raises natural killer cell activity. | A peptide extract of calf thymus from the Russian bioregulator program behind Epitalon, used as an immune drug. |
| How it works | Naturally occurring thymic peptide that modulates immune function. It stimulates T-cell maturation and NK cell activity, and has antiviral and anti-tumor effects; the anti-tumor work is mostly in cells and animals, and human results are mixed. | A peptide extract of calf thymus, one of the first two products of Vladimir Khavinson's St. Petersburg bioregulator program, used as an immune drug. Its active parts include two dipeptides the same group later made on their own: Lys-Glu (Vilon) and Glu-Trp (Thymogen). In human blood stem cells in the lab it pushed immature cells toward mature T cells, and in human immune cells it and its two dipeptides lowered the inflammatory signals IL-1β, IL-6 and TNF-α. In people, a study of 266 older adults followed for 6 to 8 years reported fewer deaths with it than in a control group, and in severe COVID-19 its developers report lower hospital mortality when it was added to basic therapy; neither study is described as randomized or blinded, and almost all of the work is by its developers. It is a different substance from thymulin and from thymosin alpha-1. |
| Commonly reported | Fewer or shorter colds over a season, with little to feel day to day. It's a prescription drug (thymalfasin) in about 35 countries, mainly for hepatitis B, though not in the US, and trial results are mixed. | Little to feel during a course; injection-site soreness is the usual complaint. |
| Studied range | Research range: 1–1.6 mg. Studied in research — not a recommendation. | No study indexed on PubMed states or tests a dose of Thymalin: the amounts people run are their own protocol, not a reference. |
| How often | 2x/week | Daily |
| Half-life | ~2 hours (Zadaxin label, after a SubQ dose) | Unknown (never measured) |
| Route | SubQ injection | IM injection, SubQ injection |
| Typical run | Community cycles typically run 4–6 weeks, 2x/week, or as needed for immune support. The hepatitis B trials ran far longer: 1.6 mg twice a week for 26 or 52 weeks (Chien 1998). | Run in short courses rather than continuously, like the other bioregulators: commonly 5–10 days, repeated months later. In the long Russian follow-up study, courses were given during the first two to three years only. No study has tested a course length. |
| Evidence | Established: clinical trials or FDA-approved use exists | Emerging: primarily preclinical / limited human data |
| Common side effects | Injection site reaction, fatigue, mild flu-like symptoms | Injection-site pain or redness, firmness at the injection site |
- Category
- Thymosin Alpha-1Healing & recovery
- ThymalinHealing & recovery
- Also known as
- Thymosin Alpha-1Tα1, Thymalfasin, Zadaxin
- ThymalinTimalin, Thymaline, Thymus peptide complex
- What it is
- Thymosin Alpha-1A naturally occurring thymic peptide that fine-tunes the immune system: it helps T-cells mature and raises natural killer cell activity.
- ThymalinA peptide extract of calf thymus from the Russian bioregulator program behind Epitalon, used as an immune drug.
- How it works
- Thymosin Alpha-1Naturally occurring thymic peptide that modulates immune function. It stimulates T-cell maturation and NK cell activity, and has antiviral and anti-tumor effects; the anti-tumor work is mostly in cells and animals, and human results are mixed.
- ThymalinA peptide extract of calf thymus, one of the first two products of Vladimir Khavinson's St. Petersburg bioregulator program, used as an immune drug. Its active parts include two dipeptides the same group later made on their own: Lys-Glu (Vilon) and Glu-Trp (Thymogen). In human blood stem cells in the lab it pushed immature cells toward mature T cells, and in human immune cells it and its two dipeptides lowered the inflammatory signals IL-1β, IL-6 and TNF-α. In people, a study of 266 older adults followed for 6 to 8 years reported fewer deaths with it than in a control group, and in severe COVID-19 its developers report lower hospital mortality when it was added to basic therapy; neither study is described as randomized or blinded, and almost all of the work is by its developers. It is a different substance from thymulin and from thymosin alpha-1.
- Commonly reported
- Thymosin Alpha-1Fewer or shorter colds over a season, with little to feel day to day. It's a prescription drug (thymalfasin) in about 35 countries, mainly for hepatitis B, though not in the US, and trial results are mixed.
- ThymalinLittle to feel during a course; injection-site soreness is the usual complaint.
- Studied range
- Thymosin Alpha-1Research range: 1–1.6 mg. Studied in research — not a recommendation.
- ThymalinNo study indexed on PubMed states or tests a dose of Thymalin: the amounts people run are their own protocol, not a reference.
- How often
- Thymosin Alpha-12x/week
- ThymalinDaily
- Half-life
- Thymosin Alpha-1~2 hours (Zadaxin label, after a SubQ dose)
- ThymalinUnknown (never measured)
- Route
- Thymosin Alpha-1SubQ injection
- ThymalinIM injection, SubQ injection
- Typical run
- Thymosin Alpha-1Community cycles typically run 4–6 weeks, 2x/week, or as needed for immune support. The hepatitis B trials ran far longer: 1.6 mg twice a week for 26 or 52 weeks (Chien 1998).
- ThymalinRun in short courses rather than continuously, like the other bioregulators: commonly 5–10 days, repeated months later. In the long Russian follow-up study, courses were given during the first two to three years only. No study has tested a course length.
- Evidence
- Thymosin Alpha-1Established: clinical trials or FDA-approved use exists
- ThymalinEmerging: primarily preclinical / limited human data
- Common side effects
- Thymosin Alpha-1Injection site reaction, fatigue, mild flu-like symptoms
- ThymalinInjection-site pain or redness, firmness at the injection site
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Thymosin Alpha-1
- Day 1–7 Your immune system is getting instructions
- Day 7–14 The immune side is ramping up
- Day 14–28 Where a common cycle ends
Thymalin
- Day 1–10 A short course, then a long gap
- Day 10–60 What the studies measured after a course
- Day 60–365 The long study in older adults
Questions people ask
How long do Thymosin Alpha-1 and thymalin last?
The half-life of Thymosin Alpha-1 is ~2 hours (Zadaxin label, after a SubQ dose). The half-life of thymalin is unknown (never measured).
How often are Thymosin Alpha-1 and thymalin taken?
Thymosin Alpha-1: 2x/week. Route: SubQ injection. Thymalin: daily. Routes: IM injection, subQ injection.
How are Thymosin Alpha-1 and thymalin dosed in research?
The research range for Thymosin Alpha-1 is 1–1.6 mg. Studied in research — not a recommendation. The library carries no reference dose for thymalin. No study indexed on PubMed states or tests a dose of Thymalin: the amounts people run are their own protocol, not a reference.
What are the common side effects of Thymosin Alpha-1 and thymalin?
For Thymosin Alpha-1, the library lists: injection site reaction, fatigue, mild flu-like symptoms. For thymalin: injection-site pain or redness, firmness at the injection site.